8-K: Vaxart Receives Nasdaq Extension to Regain Compliance with Minimum Bid Price Rule

Vaxart has been granted an extension until June 30, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Vaxart received a notice from Nasdaq on July 2, 2024, stating they were not compliant with the $1.00 minimum bid price requirement.
• The company was initially given 180 days, until December 30, 2024, to regain compliance.
• On December 31, 2024, Nasdaq granted Vaxart an additional 180-day extension, until June 30, 2025, to meet the minimum bid price requirement.
• This extension was granted because Vaxart met all other listing requirements and indicated its intention to cure the deficiency, potentially through a reverse stock split.
• If Vaxart's stock price closes at or above $1.00 for at least 10 consecutive trading days before June 30, 2025, they will regain compliance.
• Failure to regain compliance by June 30, 2025, could lead to delisting from the Nasdaq Capital Market, which the company could appeal.

Sentiment

Score: 4

Explanation: The document highlights a significant challenge for the company with the risk of delisting, but also provides a path to compliance. The extension is a positive, but the underlying issue of low stock price is a concern.

Positives

• Vaxart has been granted an additional 180 days to regain compliance, avoiding immediate delisting.
• Nasdaq acknowledged that Vaxart meets all other listing requirements, indicating underlying strength.
• The company has a clear path to regain compliance by maintaining a $1.00 share price for 10 consecutive trading days.

Negatives

• Vaxart is currently not in compliance with Nasdaq's minimum bid price requirement.
• The company's stock price has been below $1.00, triggering the non-compliance notice.
• There is no guarantee that Vaxart will be able to regain compliance by the deadline.

Risks

• There is a risk that Vaxart will not be able to increase its stock price to $1.00 for 10 consecutive trading days by June 30, 2025.
• Failure to regain compliance could result in delisting from the Nasdaq Capital Market.
• The company may need to implement a reverse stock split, which could negatively impact shareholders.
• The company's ongoing operating losses and market conditions could hinder its ability to regain compliance.

Future Outlook

Vaxart intends to actively monitor its stock price and is considering options to regain compliance with the minimum bid price requirement, including a potential reverse stock split. There is no guarantee that the company will be able to regain compliance or remain listed on the Nasdaq Capital Market.

Management Comments

• The company intends to actively monitor the closing bid price of its common stock and is considering its options to regain compliance with the Bid Price Requirement.

Industry Context

Many biotech companies, especially those in the development stage, face challenges in maintaining stock prices above minimum listing requirements. This situation is not unique to Vaxart and reflects the inherent risks in the biotech sector.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices on exchanges like Nasdaq.
• Companies like Agenus and Ocugen have also faced delisting warnings due to low stock prices, highlighting the commonality of this issue in the sector.
• Reverse stock splits are a common strategy used by companies in this situation to regain compliance, but they can be viewed negatively by investors.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company fails to regain compliance.
• Employees may be concerned about the company's future if delisting occurs.
• The company's reputation and ability to raise capital could be negatively impacted by the non-compliance notice.

Next Steps

• Vaxart will actively monitor its stock price.
• Vaxart will consider options to regain compliance, including a potential reverse stock split.
• Vaxart must achieve a minimum closing bid price of $1.00 for 10 consecutive trading days before June 30, 2025, to regain compliance.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, delisting, reverse stock split, VXRT, stock price